PubMed Health⌕ Search

Biomedical subjects

G Dietze

Publications and source records attributed to G Dietze.

At least 109 records · Page 6Linked to original sources
PubMed1975

[Twenty years of oral diabetic therapy (author's transl)].

Oral diabetic therapy can be differentiated into sulfonamide derivatives and guanidine derivatives. The substances are different with respect to mode of action, sphere of indications and side effects. In the past 20 years, preparations of both classes of substance have been considerably improved by research work and the clinical experience gained. Among the sulfonamide derivatives are preparations which are highly effective, low dosed and have few side effects. The gastro-intestinal side effects of the biguanides have been counteracted by the development of slow-release preparations. In the range of indications for oral antidiabetics, it must be noted that more important forms of treatment are available in diet and insulin therapy. Therefore, all dietetic possiblities must be exhauseted, especially in overweight diabetics, before oral antidiabetics are prescribed.

Administration, Oral↗
PubMed1975

[On the analysis of the hepatic-venous 133xenon-clearance after the application of the gas by inhalation].

After the inhalation of 133xenon continuous registrations of portal 133xenon concentrations showed that the monoexponential terminal component of the hepatic-venous 133xenon-clearance might be due to the recirculation of the gas from the gut. Accordingly, in all the cases, with the application of the wellknown "extrapolation and peeling off" of this monoexponential terminal component from this part of the hepatic-venous 133xenon-clearance, not affected any more by arterial recirculation a monoexponential 133xenon-clearance could be separated. The time-constant of the latter was similar to that of the well-knwon specific hepatic 133xenon-clearance after the application of the gas by injection into the portal vein.

Hepatic Veins↗
PubMed1975

Suitability of non-glucose-carbohydrates for parenteral nutrition.

Postoperative parenteral nutrition can only be optimally effective if the characteristics of post-traumatic metabolism are taken into account. Two main possibilities are discussed for the carbohydrate component of parenteral nutrition during this phase: glucose with high doses of insulin or non-glucose carbohydrates (sugar substitutes) possibly in a suitable combination with glucose. The risks as well as the technical and organisational problems involved in the use of them are discussed and the authors prefer the second of the two alternatives. Possible side effects of non-glucose carbohydrates are pointed out and it is shown how these can be avoided by observing dose guidelines. So far a combination of frucose : glucose : xylitol in a ratio of 2 : 1 :1 with a total dose of 0.50 g/kg/hour has been studied most thoroughly. This combination normalises the fat metabolism and improves glucose tolerance without requiring exogenous insulin. Experiences with this combination as well as individual non-glucose carbohydrates on operated patients have been given continuously for up to 7 days and in some cases even for several weeks. No side effects, no deviations from a steady state and no abnormal changes of the laboratory values occurred. The authors are of the opinion that non glucose carbohydrates are necessary if the facilities for frequent blood sugar controls are not available.

Adenine Nucleotides↗
PubMed1975

[Oxygen, carbohydrate and fat metabolism of the splanchnic region under the influence of equimolecular parenteral doses of glucose and fructose].

Hepatic metabolic balances derived from arterio-hepatic venous substrate differences and hepatic blood flow exhibited similar results during fructose and glucose infusion (10 g/5 min, 0.5 g/kg X h) as compared to those from the isolated perfused organ. Accordingly, in account of hepatic utilization of fructose glucose homeostasis and secretion maintained during fructose infusion. However, the smaller insulin response during fructose infusion did not reduce hepatic free fatty acid utilization to such an extend as to increase pyruvate oxydation. Thus, splanchnic production of lactate and pyruvate descending from fructose was enhanced leading to a 7-fold increase of arterial lactate concentration. Since hepatic venous lactate to pyruvate substrate ratios did not change, the rise of the arterial redox couple could not be due to hepatic fructose metabolism. According to the findings from the isolated perfused organ, fructose seemed to be phosphorylated at a rate which was found to be 2-3-fold that of glucose as calculated from splanchnic utilization rates. The rapid ATP-breakdown was followed by an increment in splanchnic oxygen consumption. The larger energy demand during fructose infusion seemed to be satisfied by an enhanced endoxydation of free fatty acids.

Adenosine Triphosphate↗
PubMed1975

[Influence of parenteral fructose or glucose administration on uric acid formation and phosphate uptake of the human liver].

15 min. after intravenous administration of fructose (10 g/5 min, 0,5 g/kg/h) the hepatic uric acid production in healthy volunteers increased from 0,07 mg/100 g X min to 0,52 mg/100 g X min. After one hour the enhanced uric acid production was 0,3 mg 100 g X min. The enhanced uric acid production was accompanied by an increased hepatic phosphate uptake. The highest value was 13 mumol/100 g X min. During the control period the liver released small amounts of phosphate into the hepatic vein. The increased hepatic uric acid output correlated with an enhanced renal clearance, therefore the peripheral venous uric acid concentrations remained unchanged.

Fructose↗